Figure 7: PMCA2 silencing enhances the inhibitory effects of doxorubicin on MDA-MB-231 breast cancer cell proliferation.

Cells were transfected with non-targeting siRNA (siNT) or PMCA2 siRNA (siPMCA2) for 48 h, and then pulse treated with doxorubicin (Doxo, 20 nM) for 24 h. Cell area was assessed for 59 h. Data are mean ± SD (n = 4) from 4 independent experiments, statistical significance was assessed using two-way ANOVA with Tukey’s post hoc test for each time point, *P < 0.05, for siNT vs siPMCA2; #P < 0.05, siNT vs siNT Doxo; ¤P < 0.05, siNT Doxo vs siPMCA2 Doxo; ^P < 0.05, siPMCA2 vs siPMCA2 Doxo.